Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer

European Urology

Volumn 60, Issue 6, 2011, Pages 1244-1250

  Azoulay, Laurent ^a,b   Yin, Hui ^a   Benayoun, Serge ^c   Renoux, Christel ^a   Boivin, Jean François ^a,b   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Androgen deprivation therapy; Cerebrovascular; Population based; Prostate; Stroke

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; DATABASES AS TOPIC; GENERAL PRACTICE; GREAT BRITAIN; HUMANS; ISCHEMIC ATTACK, TRANSIENT; LOGISTIC MODELS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS;

EID: 80255129259     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.08.041     Document Type: Article

References (23)

1. C. Huggins, and C. Hodges The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293 297
2. M. Braga-Basaria, D.C. Muller, M.A. Carducci, A.S. Dobs, and S. Basaria Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy Int J Impot Res 18 2006 494 498 (Pubitemid 44330303)
3. M. Braga-Basaria, A.S. Dobs, and D.C. Muller Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy J Clin Oncol 24 2006 3979 3983 (Pubitemid 46630747)
4. M.R. Smith, J.S. Finkelstein, and F.J. McGovern Changes in body composition during androgen deprivation therapy for prostate cancer J Clin Endocrinol Metab 87 2002 599 603 (Pubitemid 34158224)
5. M.R. Smith, H. Lee, M.A. Fallon, and D.M. Nathan Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer Urology 71 2008 318 322 (Pubitemid 351282338)
6. M.R. Smith Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer Urology 63 2004 742 745 (Pubitemid 38479421)
7. S.M. Alibhai, M. Duong-Hua, and R. Sutradhar Impact of androgen deprivation therapy on cardiovascular disease and diabetes J Clin Oncol 27 2009 3452 3458
8. N.L. Keating, A.J. O'Malley, S.J. Freedland, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39 46
9. H.M. Van, H. Garmo, and L. Holmberg Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden J Clin Oncol 28 2010 3448 3456
10. M.R. Cooperberg, G.D. Grossfeld, D.P. Lubeck, and P.R. Carroll National practice patterns and time trends in androgen ablation for localized prostate cancer J Natl Cancer Inst 95 2003 981 989 (Pubitemid 36896715)
11. T. Walley, and A. Mantgani The UK General Practice Research Database Lancet 350 1997 1097 1099 (Pubitemid 27437871)
12. L.A. Garcia Rodriguez, and G.S. Perez Use of the UK General Practice Research Database for pharmacoepidemiology Br J Clin Pharmacol 45 1998 419 425 (Pubitemid 28227341)
13. H. Jick, S.S. Jick, and L.E. Derby Validation of information recorded on general practitioner based computerised data resource in the United Kingdom BMJ 302 1991 766 768
14. R. Lawrenson, T. Williams, and R. Farmer Clinical information for research; the use of general practice databases J Public Health Med 21 1999 299 304 (Pubitemid 29446069)
15. R. Lawrenson, J.C. Todd, G.M. Leydon, T.J. Williams, and R.D. Farmer Validation of the diagnosis of venous thromboembolism in general practice database studies Br J Clin Pharmacol 49 2000 591 596 (Pubitemid 30326559)
16. S.S. Jick, J.A. Kaye, and C. Vasilakis-Scaramozza Validity of the general practice research database Pharmacotherapy 23 2003 686 689 (Pubitemid 36539051)
17. H. Jick, S. Jick, and L.E. Derby Calcium-channel blockers and risk of cancer Lancet 349 1997 525 528 (Pubitemid 27092790)
18. G.C. Hall, M.M. Brown, J. Mo, and K.D. MacRae Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice Neurology 62 2004 563 568 (Pubitemid 38252796)
19. H. Kaku, T. Saika, and T. Tsushima Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer Prostate 66 2006 439 444 (Pubitemid 43346954)
20. G.W. Bong, H.S. Clarke Jr., W.C. Hancock, and T.E. Keane Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer Urology 71 2008 1177 1180
21. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456 (Pubitemid 46630983)
22. E. Messing The timing of hormone therapy for men with asymptomatic advanced prostate cancer Urol Oncol 21 2003 245 254 (Pubitemid 38542727)
23. B. Nair, T. Wilt, R. MacDonald, and I. Rutks Early versus deferred androgen suppression in the treatment of advanced prostatic cancer Cochrane Database Syst Rev 2002 CD003506